NL-OMON53561
Not yet recruiting
Not Applicable
A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung Cancer - 20200469 (DeLLphi-303)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Amgen
- Enrollment
- 4
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participant has provided informed consent/assent prior to initiation of any
- •study specific activities/procedures
- •Age greater than or equal to 18 years old at the same time of signing the
- •informed consent
- •Participants with histologically or cytologically confirmed Extended Stage
- •Small Cell Lung Cancer (ES\-SCLC) and no prior systemic treatment for ES\-SCLC
- •other than protocol defined standard of care first line therapy prior to
- •enrollment. Subjects with prior treatment for limited stage SCLC (LS\-SCLC) are
- •Eastern Cooperative Oncology Group (ECOG) 0 to 1
- •Participants with treated asymptomatic brain metastases are eligible provided
Exclusion Criteria
- •History of other malignancy within the past 2 years with exceptions
- •Major surgery within 28 days of study day 1
- •Untreated or symptomatic brain metastases and leptomeningeal disease
- •Please refer to section 5\.2 of the protocol for the full list of exclusion
- •criteria and any changes in these following protocol amendment 3\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)Small Cell Lung CancerJPRN-jRCT2031220086Tagashira Shuzo50
Recruiting
Phase 1
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapyExtensive Stage Small Cell Lung CancerJPRN-jRCT2031220277Tagashira Shuzo340
Completed
Phase 2
Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate CancerProstate Cancer1003859410036958NL-OMON33942Amgen10
Recruiting
Phase 1
A Phase I Study to Evaluate the Safety and Efficacy of Mesenchymal Stromal Cells (MSC) for Treating Chronic Obstructive Pulmonary Disease (COPD)COPDRespiratory - Chronic obstructive pulmonary diseaseACTRN12614000731695Royal Perth Hospital10
Active, not recruiting
Phase 2
The Safety and Efficacy of THVD-102, a combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis.ACTRN12615000873527TheraVida, Inc21